These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34422994)

  • 21. 21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer.
    Zhang WW; Tong Q; Sun JY; Hua X; Long ZQ; Deng JP; Dong Y; Li FY; He ZY; Wu SG; Lin HX
    Front Oncol; 2019; 9():270. PubMed ID: 31041190
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
    Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database.
    Zhang Y; Liu X; Ma M; Chen C; Wang X
    Transl Cancer Res; 2023 Jul; 12(7):1741-1752. PubMed ID: 37588733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
    Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
    Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
    Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
    J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy and survival in males aged 70 years or older with breast cancer: a population-based retrospective study.
    Yu Y; Huang K; Liu Y; Chen R; Yu X; Song C
    BMC Geriatr; 2024 Mar; 24(1):282. PubMed ID: 38528444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL; Zhang JX; Fu DY
    World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.
    Zheng S; Li L; Chen M; Yang B; Chen J; Liu G; Shao Z; Wu J
    Breast; 2022 Jun; 63():177-186. PubMed ID: 35429731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
    Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
    J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Zhang L; Yu Q; Wu XC; Hsieh MC; Loch M; Chen VW; Fontham E; Ferguson T
    Breast Cancer Res Treat; 2018 May; 169(1):175-187. PubMed ID: 29368311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status.
    Zhao H; Gong Y
    Front Oncol; 2021; 11():643956. PubMed ID: 34079755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment.
    Zhu S; Li Y; Chen W; Fei X; Shen K; Chen X
    Front Oncol; 2021; 11():636266. PubMed ID: 33680973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
    Fan Y; Wang Y; He L; Imani S; Wen Q
    ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.
    Xiao Y; Li J; Wu Z; Zhang X; Ming J
    Gland Surg; 2022 Jan; 11(1):77-90. PubMed ID: 35242671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors and outcomes of completion axillary node dissection among older breast cancer patients.
    Javid SH; He H; Korde LA; Flum DR; Anderson BO
    Ann Surg Oncol; 2014 Jul; 21(7):2172-80. PubMed ID: 24585407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.